Use of Term 'Rule Out' May Delay Dermatopathology Diagnosis

Share this content:
Use of Term 'Rule Out' May Delay Dermatopathology Diagnosis
Use of Term 'Rule Out' May Delay Dermatopathology Diagnosis

TUESDAY, Nov. 1, 2016 (HealthDay News) -- In an non-integrated dermatopathology practice, use of the term "rule out" on the requisition form (RF) may cause diagnostic delays and use of unnecessary pathology services, according to a study published online Oct. 25 in the International Journal of Dermatology.

Yara Abdou, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues conducted a retrospective double-cohort study involving 475 RFs from an integrated dermatopathology practice (182 used the term "rule out" [RO] and 293 did not [NRO]) and 412 RFs from a non-integrated dermatopathology practice (126 RO and 286 NRO).

The researchers found that in the integrated practice there were no significant differences for RO and NRO patients with respect to time to diagnosis and numbers of additional tissue sections or stains applied. In the non-integrated practice, use of RFs containing the term RO correlated with significantly longer times to diagnosis and higher rates of pathology stains and sections used, compared to NRO RFs.

"Use of the term 'rule out' in RFs may not significantly impact key care delivery outcomes in an integrated practice," the authors write. "However, it may cause diagnostic delays and the use of unnecessary pathology services in a non-integrated practice."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »